US2024024344A1PendingUtilityA1

Methods For The Effective Treatment Of Metastatic Cancer

Assignee: GENERAL ONCOLOGY INCPriority: Oct 22, 2012Filed: Jul 17, 2023Published: Jan 25, 2024
Est. expiryOct 22, 2032(~6.2 yrs left)· nominal 20-yr term from priority
Inventors:Arnold Glazier
A61K 31/704A61K 31/175A61K 31/198A61K 31/5377A61K 31/69A61K 31/138A61K 35/28A61K 38/05A61K 38/07A61P 35/00A61K 31/407A61K 38/13
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods for the treatment of metastatic cancer. Methods of treating metastatic cancer by administration of a set of drugs overcome multiple mechanisms of melphalan resistance and hypersensitize cancer cells to melphalan are described. The methods involve the administration of drug(s) that induce oxidative stress in cancer cells, in conjunction with melphalan on a defined schedule.

Claims

exact text as granted — not AI-modified
1 .- 39 . (canceled) 
     
     
         40 . A combination for therapy for treating metastatic cancer or refractory metastatic cancer in a subject, comprising:
 a therapeutically effective dose of bizelesin or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective dose of bizelesin is approximately 1 μg/m 2  to approximately 20 μg/m 2 ,   bone marrow stem cells, and   an MDR-1 pgp pump inhibitor or a pharmaceutically acceptable salt thereof, wherein the MDR-1 pgp pump inhibitor is erythromycin in an amount of approximately 3 mg/kg to approximately 5 mg/kg every 6 hours with a maximum of 4 grams/day.

Join the waitlist — get patent alerts

Track US2024024344A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.